Top Stocks Ytd
Top Stocks Ytd
BioRunUp Review – Riding The Waves Of Biotech
BioRunUp was created in 2010 by Mark Messier, below is his story
“When I graduated high school I began working at Bank of America (BAC) while attending college. Seeing the price of BAC fall to $3 a share, I had a sense that this was a good time to buy. At the time I didn’t have much of a trading account, but I managed to buy about 1500 shares. The recent upturn of the financial industry increased my portfolio and gave me the confidence and opportunity to branch out in other areas of the market. That is when I discovered biotechs.
CTIC will always hold a special place in my heart, it was the first biotech that I ever traded. I bought a few thousand shares in the $.30 range, and watched it grow to well over $1. Next was HEB. Although now former “HEBber’s” view that stock as a nightmare, I watch my original buy of $.96 climb to $4.54. This ignited my interest in biotech stocks. The more research I performed the more excited I got. There seems to be a semi-predictable pattern with FDA Catalyst stocks.
Simply put- Buy early, let the anticipation drive the price up, then sell. However, it is not that simple. In this confusing sector there was no reliable source of legitimate FDA catalysts. From this void BioRunUp was created.
I have always had a simplistic view of money. It is not what makes you happy. This viewpoint is very contrary to the majority on Wall Street to whom money is everything. These feelings only grew once we had our first child in 2007. We spent the first 7 years of our marriage traveling as much as possible. The tropical climate has always appealed to us, and we made a few trips down to Costa Rica, before purchasing a piece of land on the Pacific coast in 2007. I look forward to living and trading in a relaxed tropical climate and spending more time with my family. This is something life in cubicle-ville can never offer.
Successful Trading
In 2009 my biotech portfolio increased by 273%, and another 216% in 2010.
Let’s Ride the Waves of Biotech Together
Riding the ups and downs of biotech’s can be a mix of skill and timing. It does not look like this sector will be going anywhere any time soon. As long as there is sickness, there will be a biotech market. With a healthy combination of run-ups, free shares, shorting, and options I feel there is a huge potential in these plays. That being said, lets go ride the waves.”
==> Visit BioRunUp Official Website
For those not familiar with the Run-Up method, here is the concept:
Biotech companies spend between $325M and $750M from development to approval of a new drug, a process that takes about 8-10 years. This begins with the creation of the drug, then is followed by phase I, II, and III clinical trials- all under the watchful eye of the FDA. Only at this point are some drugs assigned a date, at which approval or denial is to be announced. This decision date is known at least 6 months in advance. The Run-Up method involves locating and buying shares of these companies well before their decision date, riding the share price up, and selling BEFORE the FDA announces their decision. The concept can also be applied to clinical trials with data releases. The goal is simple: Minimize risk while maximizing consistent profits.
This system has a proven track record of success. In 2009 my biotech portfolio gained 273%, in 2010 216%, and 155% 2011 YTD. The concept seems simple- buy early, hold, and sell before the catalyst. However, it can be quite complicated. What is the key to successfully trading biotech catalyst events?
Research, Research, and more Research By the time you hear about one of these stocks in the news it is too late. The best profits are made by getting in before the masses. This is what BioRunUp.com subscription service provides for you. We are constantly researching and using every resource available to find the next catalyst event. Some of our sources include:
- Paid Subscription Services – SEC Filings – News Feed Searches – Phase III Trial Results – Forums & Bulletin Boards – Company Websites Not every FDA or Clinical catalyst will result in a run-up. When taking into account what stocks to discuss we take into account many factors, including (but not limited to) the following: – Company Market Cap – Drug Type (Potential Market) – Cash on Hand (Dilution) – Perception of Approval Odds – New NDA or Re-Submission – Is an FDA Panel Scheduled – Partnerships – Management Reputation
As you can see, this is not a simple process. Many hours of careful research and analysis is required for each and every stock. The majority of the stocks we research do not meet our strict criteria and are not published.
==> Visit BioRunUp Official Website
Shaoul – on Global macro, Central Banks, Gold & Silver, Tech & EMs
